Ocumension Therapeutics announced that its board approved a change in the use of unspent funds from both its 2020 initial public offering and its 2021 share placing, shifting the remaining HK$121.87 million toward working capital and other general corporate purposes.

The company originally raised HK$1.65 billion in net proceeds from its IPO. As of 30 June 2026, 92.4 % (HK$1.52 billion) had been deployed, leaving HK$124.97 million unused. On 28 August 2026, the board resolved to reallocate HK$102.50 million of this residual balance—previously earmarked mainly for OT-401 research, development, and milestone payments—to general corporate uses. Management targets full utilisation of the remaining IPO balance by end-2027.

From the January 2021 placing, Ocumension generated HK$782.60 million in net proceeds. By 30 June 2026, 97.5 % (HK$762.34 million) had been spent, with HK$19.37 million still unutilised. This amount, once intended for international multi-center trials and OT-1001-related work, will likewise be redirected to working capital and broader corporate needs, also expected to be fully applied by end-2027.

The board cited two main factors for the reallocation: (1) remaining R&D expenditure for OT-401 and OT-1001 is now deemed limited after commercial progress and milestone completions; and (2) the group’s funding requirements have broadened as more products enter the commercialization phase, necessitating greater financial flexibility for sales, marketing, market access, compliance, and other operational activities.

Ocumension emphasized that the adjustments do not alter its core business strategy or adversely affect ongoing operations. The company maintains that aligning unused funds with current development priorities is in the best interests of shareholders and supports its transition to a more commercially driven pharmaceutical model.